These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 22127594)

  • 1. General insufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients' medical treatment or underlying diseases.
    Schlaf G; Mauz-Körholz C; Ott U; Leike S; Altermann W
    Histol Histopathol; 2012 Jan; 27(1):31-8. PubMed ID: 22127594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies.
    Schlaf G; Apel S; Wahle A; Altermann WW
    Biomed Res Int; 2015; 2015():587158. PubMed ID: 25654115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic flow cytometric crossmatch in renal transplantation: a single assay to simultaneously detect antibody binding and cytotoxicity.
    Thammanichanond D; Athimang W; Paisooksantivatana K; Mongkolsuk T; Ingsathit A; Worawichawong S; Kitpoka P; Jirasiritham S; Kantachuvesiri S
    Transplant Proc; 2012 Jan; 44(1):62-5. PubMed ID: 22310580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study between cytotoxicity and flowcytometry crossmatches before and after renal transplantation.
    Abdel Rahman AS; Fahim NM; El Sayed AA; El Hady SA; Ahmad YS
    Egypt J Immunol; 2005; 12(2):77-89. PubMed ID: 17977213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luminex Solid-Phase Crossmatch for De Novo Donor-Specific Antibodies in Living-Donor Related Transplants.
    Mehrotra S; Sharma RK; Mayya M; Gupta A; Prasad N; Kaul A; Bhadauria DS
    Exp Clin Transplant; 2017 Aug; 15(4):394-399. PubMed ID: 28447925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation.
    Gloor JM; DeGoey S; Ploeger N; Gebel H; Bray R; Moore SB; Dean PG; Stegall MD
    Transplantation; 2004 Jul; 78(2):221-7. PubMed ID: 15280682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation.
    Morris GP; Phelan DL; Jendrisak MD; Mohanakumar T
    Hum Immunol; 2010 Mar; 71(3):268-73. PubMed ID: 20074605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel ELISA-based crossmatch procedure to detect donor-specific anti-HLA antibodies responsible for corneal allograft rejections.
    Sel S; Schlaf G; Schurat O; Altermann WW
    J Immunol Methods; 2012 Jul; 381(1-2):23-31. PubMed ID: 22561526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
    Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
    Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure.
    Altermann WW; Seliger B; Sel S; Wendt D; Schlaf G
    Histol Histopathol; 2006 Oct; 21(10):1115-24. PubMed ID: 16835834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation.
    Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Hallar M; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Transpl Immunol; 2008 Nov; 20(1-2):61-7. PubMed ID: 18929659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified flow cytometry crossmatch detecting alloantibody-related cytotoxicity as a way to distinguish lytic antibodies from harmless in allosensitised kidney recipients.
    Zieliński M; Zielińska H; Moszkowska G; Dȩbska-Ślizień A; Rutkowski B; Trzonkowski P
    Transplant Proc; 2013; 45(1):88-94. PubMed ID: 23375279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assignment of C1q-binding HLA antibodies as unacceptable HLA antigens avoids positive CDC-crossmatches prior to transplantation of deceased donor organs.
    Juhl D; Marget M; Hallensleben M; Görg S; Ziemann M
    Transpl Immunol; 2017 Mar; 41():17-21. PubMed ID: 28088367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance.
    Waki K; Sugawara Y; Mizuta K; Fujita H; Kadowaki T; Kokudo N
    Clin Transpl; 2011; ():223-35. PubMed ID: 22755416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization.
    Ata P; Canbakan M; Kara M; Özel L; Ünal E; Titiz Mİ
    Transplant Proc; 2012; 44(6):1652-5. PubMed ID: 22841237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch.
    Mahmoud KM; Ismail AM; Sheashaa HA; Gheith OA; Kamal MM; Ghoneim MA
    Exp Clin Transplant; 2009 Jun; 7(2):124-8. PubMed ID: 19715518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-dependent cytotoxicity crossmatch in solid organ transplantation: The gold standard or golden history?
    Tafulo S; Osório E; Mendes C; Liwski R
    Hum Immunol; 2024 Jan; 85(1):110734. PubMed ID: 38030522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.